Sign in
CompletedPhase 3

CONDYVAC. Efficacy study of the quadrivalent Human Papilloma Virus (HPV) vaccine to prevent recurrence of External Genital Warts (EGW) in patients who were cured in the first place

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
France13 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
300 people enrolled
Started
11 Jan 2018
Ended
4 Nov 2025
Type of study
Interventional
Record updated
10 December 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Patients aged 18 years and older
  • Patients who, after the nature of the study has been explained to them, and prior to any protocol specific procedures being performed, have given written consent according to local regulatory requirements
  • Patients with a confirmed clinical diagnosis for previous external anogenital warts
  • Patient completely cured (no clinically visible lesions) for over two weeks and less than a month prior to inclusion visit (V1, M0) after initial success of classic treatment
  • Women of childbearing potential must have a negative pregnancy test and an effective contraception from selection visit (V0) and up to the end of the vaccination period of 6 months
  • Males must have an effective protection with condoms in order to limit the risk of recontamination from selection visit (V0) and up to the end of the vaccination period of 6 months
  • Patients affiliated to a social security regimen
  • Patients able to participate during the 12 months of the study

Who cannot take part

  • Patients participating in any clinical trial with another investigational product 28 days prior to first study visit or intent on participating in another clinical study at any time during the conduct of this study
  • Patients who received the HPV Vaccine at any time before enrolment to the study
  • Patients with positive HIV, HCV or HBV (Ag HBS) tests
  • Patients whose regular partner(s) have an active uncontrolled clinical EGW disease
  • Patients with any serious chronic or progressive disease according to the judgment of the investigator
  • Patients with history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or under immunosuppressive therapy including use of systemic corticosteroids or chronic immunosuppressant medication (more than 14 days) (i.e. prednisone, or equivalent ≥10 mg/day) within : • the 28 days preceding the first vaccination at the inclusion visit V1 in case of corticosteroids administration • the 3 months preceding the first vaccination at the inclusion visit V1 in case of administration of cyclophosphamide, anti-TNF- alpha, intravenous immunoglobulins, abatacep, corticosteroids as a bolus injection • the 6 months preceding the first vaccination at the inclusion visit V1 in case of anti CD 20 administration or in chemotherapy treatment within the past 180 days (6 months).Topical or inhaled uses of steroid including intranasal are allowed
  • Patients with history of known allergies/hypersensitivity to any component of study vaccine
  • Patients who have any malignancy or lymphoproliferative disorder
  • Patients with thrombocytopenia or coagulation disorder contre- indicating intramusculary injections
  • Women who are pregnant or are breast-feeding, or are of childbearing age and do not use or do not plan to use acceptable birth control measures, during the first 6 months of the study
  • Patient with diagnosis of internal anogenital warts (intra rectal , intra vaginal, intra urethral) at the selection visit
  • Male who do not use or do not plan to use condoms, during the first 6 months of the study
  • Patients under a measure of legal protection or unable to consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate if the HPV vaccine, as compared to placebo, reduces the relapse rate of external genital warts over a 12 month-period after their first injection

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
10 December 2024